Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review.

Alsuhebany, Nada; Pan, Congshan; Holovac, Eileen; Do, Brian; McBride, Ali

Alsuhebany, Nada; Pan, Congshan; Holovac, Eileen; Do, Brian; McBride, Ali.

Afiliação

Alsuhebany N; College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia.
Pan C; King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia.
Holovac E; King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia.
Do B; Department of Oncology Pharmacy, University of Arizona Cancer Center, Tucson, AZ, USA.
McBride A; Department of Oncology Pharmacy, VA Loma Linda Healthcare System, Loma Linda, CA, USA.

Blood Lymphat Cancer ; 13: 67-76, 2023.

Article em En | MEDLINE | ID: mdl-38034984

Palavras-chave

Bruton's tyrosine kinase inhibitor; mantle cell lymphoma; zanubrutinib

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Blood Lymphat Cancer Ano de publicação: 2023 Tipo de documento: Article